Tetra Bio-Pharma and Cellvera to develop ARDS-003 in combination with favipiravir for COVID-19
Sep. 7, 2022
Tetra Bio-Pharma Inc. has signed an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 (onternabez) as a combination product with Qifenda (favipiravir) 400 mg, a commercial-stage broad-spectrum antiviral drug.